Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

New technique for diabetes treatment may be in the offing

An exploration of the molecular links between insulin resistance and inflammation may have revealed a novel target for diabetes treatment, say scientists at the John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh of UPMC. Their findings were published earlier this month in the online version of Diabetes, one of the journals of the American Diabetes Association.

27 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

Obesity is on a rampage, with the World Health Organization pegging the numbers at more than 300 million worldwide, with a billion more overweight. With obesity comes the increased risk for cardiovascular disease, Type II diabetes, and hypertension.

25 Aug 2009

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Mild glucose intolerance in pregnancy may be an early identifier of women who are at increased risk of heart disease in the future, found a new study http://www.cmaj.ca/press/cmaj090569.pdf published in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

25 Aug 2009

The Center for Health Value Innovation to support the National Diabetes Goal

The Center for Health Value Innovation, the nation’s premier information exchange for value-based design, today joined with other non-profits, healthcare provider groups, universities, government officials, and corporations to fully support the National Diabetes Goal (NDG) which aims to increase awareness and improve the management of type 2 Diabetes to the 45 percent of Americans at risk.

24 Aug 2009

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Low levels of vitamin D are known to nearly double the risk of cardiovascular disease in patients with diabetes, and researchers at Washington University School of Medicine in St. Louis now think they know why.

24 Aug 2009

Takeda Canada reacquires commercial rights for an oral type 2 diabetic treatment drug

Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.

21 Aug 2009

Wheat-free diet reduces the incidence of diabetes

Scientists at the Ottawa Hospital Research Institute and the University of Ottawa have discovered what may be an important clue to the cause of type 1 diabetes. Dr. Fraser Scott and his team tested 42 people with type 1 diabetes and found that nearly half had an abnormal immune response to wheat proteins. The study is published in the August 2009 issue of the journal Diabetes.

21 Aug 2009

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population-based cohort study

Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug (pioglitazone), concludes a study published on bmj.com today.

20 Aug 2009

Nutrisystem's 28-Day program maintains an affordable per-meal cost

Nutrisystem, Inc., a leading provider of weight management products and services that are delivered directly to the customers' doors, announced today that its popular 28-Day Nutrisystem Select program now includes an additional week of delicious fresh-frozen entrees - all for the same low monthly cost.

20 Aug 2009

Surgeons of BMI of Texas selected to host a preceptorship for using REALIZE Adjustable Gastric Band

The Bariatric Medical Institute of Texas (“BMI of Texas”) today announced surgeons Mickey Seger and Terive Duperier have been selected by Ethicon Endo-Surgery, Inc. as one of the five training sites in the U.S. to host a preceptorship for the Ethicon Endo-Surgery REALIZE™ Adjustable Gastric Band.

20 Aug 2009

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.

18 Aug 2009

Tissue scarring key to link between obesity and diabetes

The team, in collaboration with University Hospital Aintree, the University of Warwick and researchers in Sweden, found that people classified as obese and those with pre-diabetes have raised levels of a protein called SPARC, that can cause tissue scarring.

13 Aug 2009

Meal replacements in a medically supervised weight loss program aid weight loss

Meal replacements in a medically supervised weight loss program are successful in facilitating weight loss, according to a new study conducted at the University of Kentucky. The study appears in the August 2009 issue of the Journal of the American Dietetic Association.

12 Aug 2009

VIVUS reports Q2 2009 financials

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter ended June 30, 2009.

11 Aug 2009

Easy-to-swallow drug restores autoimmune function in diabetics

Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials. Now, new research published in the June issue of the European Journal of Pharmacology shows that the drug might be able to slow the progression of diabetes as well.

11 Aug 2009

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa’s efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.

11 Aug 2009

Insulin and type 2 diabetes - fears are largely unfounded

People diagnosed with type 2 diabetes often resist taking insulin because they fear gaining weight, developing low blood sugar and seeing their quality of life decline.

11 Aug 2009

Discovery of gene that may play a role in the development of type 1 diabetes

Scientists at Stanford University have identified a gene that may play a role in the development of type 1 diabetes, an autoimmune disease in which the immune system attacks the body's insulin-producing cells. Insulin, a hormone produced by cells of the pancreas, helps the body to absorb sugars found in food and to maintain blood sugar at appropriate levels.

10 Aug 2009

Discovery of gene linked to maturity-onset diabetes of the young

Researchers at the Joslin Diabetes Center have linked another gene to a rare form of diabetes, a finding that could prove beneficial to those with the more common type 2 diabetes.

10 Aug 2009

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

New technique for diabetes treatment may be in the offing

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

The Center for Health Value Innovation to support the National Diabetes Goal

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Takeda Canada reacquires commercial rights for an oral type 2 diabetic treatment drug

Wheat-free diet reduces the incidence of diabetes

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population-based cohort study

Nutrisystem's 28-Day program maintains an affordable per-meal cost

Surgeons of BMI of Texas selected to host a preceptorship for using REALIZE Adjustable Gastric Band

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

Tissue scarring key to link between obesity and diabetes

Meal replacements in a medically supervised weight loss program aid weight loss

VIVUS reports Q2 2009 financials

Easy-to-swallow drug restores autoimmune function in diabetics

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Insulin and type 2 diabetes - fears are largely unfounded

Discovery of gene that may play a role in the development of type 1 diabetes

Discovery of gene linked to maturity-onset diabetes of the young

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in